Amsterdam - Delayed Quote EUR

Vivoryon Therapeutics N.V. (VVY.AS)

1.7540
-0.0040
(-0.23%)
At close: May 14 at 5:35:29 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
-3,620
0
10,764
Cost of Revenue
0
0
-525
0
1,569
Gross Profit
0
0
-3,095
0
9,196
Operating Expense
20,964
20,964
25,742
29,059
22,094
Operating Income
-20,964
-20,964
-28,837
-29,059
-12,898
Net Non Operating Interest Income Expense
396
396
261
18
-3
Pretax Income
-20,568
-20,568
-28,576
-28,355
-12,223
Tax Provision
0
0
-234
-199
432
Net Income Common Stockholders
-20,568
-20,568
-28,342
-28,156
-12,655
Diluted NI Available to Com Stockholders
-20,568
-20,568
-28,342
-28,156
-12,655
Basic EPS
-1.20
-0.79
-1.12
-1.28
-0.63
Diluted EPS
-1.20
-0.79
-1.12
-1.28
-0.63
Basic Average Shares
25,294.5980
26,035.4430
25,305.3570
22,019.5570
20,000.0140
Diluted Average Shares
25,294.5980
26,035.4430
25,305.3570
22,019.5570
20,000.0140
Total Operating Income as Reported
-20,964
-20,964
-28,837
-29,113
-12,798
Total Expenses
20,964
20,964
25,217
29,059
23,663
Net Income from Continuing & Discontinued Operation
-20,568
-20,568
-28,342
-28,156
-12,655
Normalized Income
-20,568
-20,568
-28,342
-28,148.0561
-12,601.8000
Interest Income
482
482
726
42
21
Interest Expense
86
86
465
24
24
Net Interest Income
396
396
261
18
-3
EBIT
-20,482
-20,482
-28,111
-28,331
-12,199
EBITDA
-20,335
-20,335
-27,944
-28,170
-12,034
Reconciled Cost of Revenue
0
0
-525
0
1,569
Reconciled Depreciation
147
147
167
161
165
Net Income from Continuing Operation Net Minority Interest
-20,568
-20,568
-28,342
-28,156
-12,655
Total Unusual Items Excluding Goodwill
--
--
0
-8
-76
Total Unusual Items
--
--
0
-8
-76
Normalized EBITDA
-20,335
-20,335
-27,944
-28,162
-11,958
Tax Rate for Calcs
0
0
0
0
0.0003
Tax Effect of Unusual Items
0
0
0
-0.0561
-22.8000
12/31/2021 - 10/27/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1IJA.MU Adicet Bio Inc
0.5870
-4.24%
 
473A.SG Adaptimmune Therapeutics PLC
0.2360
-1.67%
 
3G0.BE Altimmune Inc
5.06
-1.52%
 
HPHA.BE Heidelberg Pharma AG
3.2700
+3.48%
 
MARI.VI Marinomed Biotech AG
12.35
+1.65%
 
FYB.DE Formycon AG
23.20
+0.22%
 
41X.F Ardelyx, Inc.
2.8850
-3.64%
 
HPHA.DE Heidelberg Pharma AG
3.1200
-1.58%
 
VSC.F 4SC AG
2.4800
0.00%
 
BIOV.SW BioVersys N
34.70
0.00%